{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:17:25Z","timestamp":1783682245222,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40262-020-00899-7","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T23:34:40Z","timestamp":1590449680000},"page":"1451-1466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population Pharmacokinetic\u2013Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"59","author":[{"given":"Lei","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Paccaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanaja","family":"Kanamaluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"899_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392:1789\u2013858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"899_CR2","doi-asserted-by":"publisher","first-page":"698313","DOI":"10.1155\/2014\/698313","volume":"2014","author":"Y Yoshida","year":"2014","unstructured":"Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313.","journal-title":"Biomed Res Int"},{"key":"899_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthr Rheumatol. 2017;69:277\u201390.","journal-title":"Arthr Rheumatol"},{"key":"899_CR4","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthr Rheumatol. 2015;67:1424\u201337.","journal-title":"Arthr Rheumatol"},{"key":"899_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840\u20137.","journal-title":"Ann Rheum Dis"},{"key":"899_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrrheum.2015.58","volume":"11","author":"EM Ruderman","year":"2015","unstructured":"Ruderman EM. Rheumatoid arthritis: IL-6 inhibition in RA\u2014deja vu all over again? Nat Rev Rheumatol. 2015;11:321\u20132.","journal-title":"Nat Rev Rheumatol"},{"key":"899_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40265-017-0724-2","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ. Sarilumab: first global approval. Drugs. 2017;77:705\u201312.","journal-title":"Drugs"},{"key":"899_CR8","unstructured":"Kevzara. US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761037s000lbl.pdf. Cited Sep 2019."},{"key":"899_CR9","unstructured":"Kevzara. Summary of product characteristics. 2019. https:\/\/www.medicines.org.uk\/emc\/medicine\/33836. Cited 12 Aug 2019."},{"key":"899_CR10","unstructured":"Sebastien B, Sun S, Rigaux-Lampe C, Quan H, Paccaly A, Lin Y, et al. Benefit\/risk assessment of sarilumab using exposure\/response modeling of key efficacy and safety endpoints in patients with rheumatoid arthritis. American conference on pharmacometrics (ACoP) 10, Vol 1; 2019; Orlando, FL. ISSN:2688-3953."},{"key":"899_CR11","unstructured":"Meng Z, Sebastien B, Sun S, Rigaux-Lampe C, Paccaly A, Xu C, et al. Exposure\/response modeling for sarilumab dose regimens benefit\/risk assessment. Population Approach Group in Europe (PAGE) meeting 2017: Budapest; 2017. p. 7285."},{"key":"899_CR12","doi-asserted-by":"publisher","first-page":"H2954","DOI":"10.1152\/ajpheart.2000.279.6.H2954","volume":"279","author":"T Suwa","year":"2000","unstructured":"Suwa T, Hogg JC, English D, Van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000;279:H2954\u2013H29602960.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"899_CR13","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Lin Y, John GS, Heijde Dvd, Qiu C, Gomez-Reino JJ, et al. Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. Ann Rheum Dis. 2019;78 Suppl 2:1130\u20131.","DOI":"10.1136\/annrheumdis-2019-eular.245"},{"key":"899_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40262-019-00765-1","volume":"58","author":"C Xu","year":"2019","unstructured":"Xu C, Su Y, Paccaly A, Kanamaluru V. Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis. Clin Pharmacokinet. 2019;58:1455\u201367.","journal-title":"Clin Pharmacokinet"},{"key":"899_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10928-011-9227-z","volume":"39","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Frey N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn. 2012;39:5\u201316.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"899_CR16","doi-asserted-by":"crossref","unstructured":"Kovalenko P, Paccaly A, Boyapati A, Xu C, Davis J, DiCioccio T. Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of single-dose sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA). 9th American conference on pharmacometrics, Fort Lauderdale, FL; 2017.","DOI":"10.1002\/psp4.12534"},{"key":"899_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1136\/annrheumdis-2018-eular.1375","volume":"2018","author":"T Ishii","year":"2018","unstructured":"Ishii T, Sato Y, Munakata Y, Kajiwara M, Takahashi Y, Anwar F, et al. AB0472 pharmacodynamic effect and safety of single-dose sarilumab sc or tocilizumab iv or sc in patients with rheumatoid arthritis (RA). Ann Rheum Dis. 2018;2018:1397\u20138.","journal-title":"Ann Rheum Dis"},{"key":"899_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","volume":"53","author":"HL Wright","year":"2014","unstructured":"Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford). 2014;53:1321\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"899_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/eci.12799","volume":"47","author":"LSC Lok","year":"2017","unstructured":"Lok LSC, Farahi N, Juss JK, Loutsios C, Solanki CK, Peters AM, et al. Effects of tocilizumab on neutrophil function and kinetics. Eur J Clin Invest. 2017;47:736\u201345.","journal-title":"Eur J Clin Invest"}],"updated-by":[{"DOI":"10.1007\/s40262-026-01656-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00899-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00899-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00899-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:38:42Z","timestamp":1783679922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00899-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00899-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"26 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct a value in Table 4.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40262-026-01656-y","URL":"https:\/\/doi.org\/10.1007\/s40262-026-01656-y","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Christine Xu and Vanaja Kanamaluru are employees of Sanofi Genzyme and may hold stock and\/or stock options in the company. Lei Ma was an employee of Sanofi Genzyme at the time of this work and may hold stock and\/or stock options in the company. Anne Paccaly is an employee of Regeneron Pharmaceuticals, Inc and may hold stock and\/or stock options in the company. None of the authors have any non-financial conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For each individual study, all procedures were in accordance with the ethical standards of the relevant institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the individual studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}